Innate Pharma S.A. ADR (IPHA)

$1.82 0.00 (N/A)
Market Cap 167.78M
Revenue (ttm) 21.77M
Net Income (ttm) -53.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -245.89%
Debt to Equity Ratio 5.25
Volume 36,600
Avg Vol 239,146
Day's Range N/A - N/A
Shares Out 92.19M
Stochastic %K 12%
Beta 0.09
Analysts Sell
Price Target $4.40

Company Profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 4 30 30 30 30
Fax: 33 4 30 30 30 00
Address:
117, Avenue de Luminy, BP 30191, Marseille, France
UgoGreg
UgoGreg Nov. 11 at 4:35 PM
$IPHA https://youtu.be/rUHW24bmO0c
0 · Reply
Hekinsieden
Hekinsieden Nov. 10 at 11:50 PM
$IPHA $BNAI $GLTO $CAPS
0 · Reply
topstockalerts
topstockalerts Nov. 10 at 11:10 PM
Top Gainers PT2 $SWAG $GREE $IRWD $SKYT $IPHA
0 · Reply
topstockalerts
topstockalerts Nov. 10 at 9:42 PM
Top Gainers PT2 $SWAG $GREE $IRWD $SKYT $IPHA
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 10 at 8:53 PM
$GLTO 4%[243%] $IPHA -3%[32%] $HKIT 3%[86%] most notable movement into the final minutes of trading.
0 · Reply
MS_Tammy
MS_Tammy Nov. 10 at 8:32 PM
$IPHA $BNAI $GLTO $CAPS me done for the day.,Well done to everyone who made money today ..I see you all tomorrow and thanks for your trust and support as usual..follow us to make money. All free info on Stocktwits.. do not pay anyone your hard earned money for useless alerts.
9 · Reply
neo55
neo55 Nov. 10 at 8:24 PM
$IPHA I see this going to 3 by end of week GL
0 · Reply
A1DAYTRADER
A1DAYTRADER Nov. 10 at 8:15 PM
$IPHA 👀🤫💵 $HKIT 🤫🚀👀 $VCIG $SELX $GLTO $MOVE.X $BNAI $MSGY
0 · Reply
UltimateWackDumbtrader27
UltimateWackDumbtrader27 Nov. 10 at 8:07 PM
$IPHA FDA clearance news of phase 3s usually have a brutal bullish run. 
0 · Reply
notreload_ai
notreload_ai Nov. 10 at 5:08 PM
$IPHA is moving forward with the TELLOMAK 3 trial for lacutamab in advanced cutaneous T-cell lymphomas (CTCL), including Sézary syndrome (SS) and Mycosis fungoides (MF). https://notreload.xyz/fda-clears-lacutamab-confirmatory-phase-3-ctcl-trial-protocol/
0 · Reply
Latest News on IPHA
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 5:21 PM EST - 3 days ago

Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Nov 13, 2025, 1:00 AM EST - 4 days ago

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

Nov 10, 2025, 1:00 AM EST - 7 days ago

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

Nov 5, 2025, 1:00 AM EST - 12 days ago

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript

Oct 28, 2025, 6:21 PM EDT - 19 days ago

Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

Oct 14, 2025, 1:00 AM EDT - 4 weeks ago

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript

Sep 17, 2025, 11:43 AM EDT - 2 months ago

Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript

Innate Pharma Reports First Half 2025 Business Update and Financial Results

Sep 17, 2025, 1:00 AM EDT - 2 months ago

Innate Pharma Reports First Half 2025 Business Update and Financial Results

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

Sep 15, 2025, 1:00 AM EDT - 2 months ago

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

Sep 10, 2025, 4:30 AM EDT - 2 months ago

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

Jul 29, 2025, 1:00 AM EDT - 3 months ago

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

Jun 17, 2025, 1:00 AM EDT - 5 months ago

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Jun 13, 2025, 1:00 AM EDT - 5 months ago

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025, 1:00 AM EDT - 6 months ago

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

May 23, 2025, 1:00 AM EDT - 6 months ago

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Outcome of Innate Pharma's 2025 Annual General Meeting

May 23, 2025, 1:00 AM EDT - 6 months ago

Outcome of Innate Pharma's 2025 Annual General Meeting

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

May 19, 2025, 1:00 AM EDT - 6 months ago

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

May 15, 2025, 1:00 AM EDT - 6 months ago

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

May 13, 2025, 1:51 PM EDT - 6 months ago

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

May 13, 2025, 1:00 AM EDT - 6 months ago

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Innate Pharma announces conference call and webcast for Q1 2025 business update

May 6, 2025, 1:00 AM EDT - 6 months ago

Innate Pharma announces conference call and webcast for Q1 2025 business update

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

Apr 30, 2025, 11:30 AM EDT - 7 months ago

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Apr 29, 2025, 3:00 PM EDT - 7 months ago

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Innate Pharma Announces €15M Investment by Sanofi

Apr 24, 2025, 1:35 AM EDT - 7 months ago

Innate Pharma Announces €15M Investment by Sanofi

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

Apr 23, 2025, 1:00 AM EDT - 7 months ago

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Apr 16, 2025, 1:00 AM EDT - 7 months ago

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Apr 16, 2025, 1:00 AM EDT - 7 months ago

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

Apr 3, 2025, 1:00 AM EDT - 8 months ago

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:49 PM EDT - 8 months ago

Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Mar 27, 2025, 2:00 AM EDT - 8 months ago

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

Mar 26, 2025, 2:00 AM EDT - 8 months ago

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

Mar 25, 2025, 2:00 AM EDT - 8 months ago

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

Innate Pharma: Moving Into The Padcev Space

Mar 21, 2025, 9:10 AM EDT - 8 months ago

Innate Pharma: Moving Into The Padcev Space

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 20, 2025, 2:00 AM EDT - 8 months ago

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Feb 27, 2025, 1:00 AM EST - 9 months ago

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion

Feb 20, 2025, 11:39 AM EST - 9 months ago

Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Feb 17, 2025, 1:02 AM EST - 9 months ago

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Jan 27, 2025, 1:00 AM EST - 10 months ago

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Jan 21, 2025, 1:00 AM EST - 10 months ago

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Jan 10, 2025, 1:00 AM EST - 11 months ago

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 1:00 AM EST - 11 months ago

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Dec 9, 2024, 1:00 AM EST - 1 year ago

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Dec 6, 2024, 1:00 AM EST - 1 year ago

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Dec 3, 2024, 1:00 AM EST - 1 year ago

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Innate Pharma: Looking Like A Company We'll Regret Ignoring

Nov 25, 2024, 11:54 AM EST - 1 year ago

Innate Pharma: Looking Like A Company We'll Regret Ignoring

Innate Pharma Releases Its 2025 Financial Calendar

Nov 20, 2024, 1:00 AM EST - 1 year ago

Innate Pharma Releases Its 2025 Financial Calendar

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Nov 19, 2024, 1:00 AM EST - 1 year ago

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 1:09 PM EST - 1 year ago

Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Nov 13, 2024, 1:00 AM EST - 1 year ago

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Nov 8, 2024, 1:00 AM EST - 1 year ago

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

UgoGreg
UgoGreg Nov. 11 at 4:35 PM
$IPHA https://youtu.be/rUHW24bmO0c
0 · Reply
Hekinsieden
Hekinsieden Nov. 10 at 11:50 PM
$IPHA $BNAI $GLTO $CAPS
0 · Reply
topstockalerts
topstockalerts Nov. 10 at 11:10 PM
Top Gainers PT2 $SWAG $GREE $IRWD $SKYT $IPHA
0 · Reply
topstockalerts
topstockalerts Nov. 10 at 9:42 PM
Top Gainers PT2 $SWAG $GREE $IRWD $SKYT $IPHA
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 10 at 8:53 PM
$GLTO 4%[243%] $IPHA -3%[32%] $HKIT 3%[86%] most notable movement into the final minutes of trading.
0 · Reply
MS_Tammy
MS_Tammy Nov. 10 at 8:32 PM
$IPHA $BNAI $GLTO $CAPS me done for the day.,Well done to everyone who made money today ..I see you all tomorrow and thanks for your trust and support as usual..follow us to make money. All free info on Stocktwits.. do not pay anyone your hard earned money for useless alerts.
9 · Reply
neo55
neo55 Nov. 10 at 8:24 PM
$IPHA I see this going to 3 by end of week GL
0 · Reply
A1DAYTRADER
A1DAYTRADER Nov. 10 at 8:15 PM
$IPHA 👀🤫💵 $HKIT 🤫🚀👀 $VCIG $SELX $GLTO $MOVE.X $BNAI $MSGY
0 · Reply
UltimateWackDumbtrader27
UltimateWackDumbtrader27 Nov. 10 at 8:07 PM
$IPHA FDA clearance news of phase 3s usually have a brutal bullish run. 
0 · Reply
notreload_ai
notreload_ai Nov. 10 at 5:08 PM
$IPHA is moving forward with the TELLOMAK 3 trial for lacutamab in advanced cutaneous T-cell lymphomas (CTCL), including Sézary syndrome (SS) and Mycosis fungoides (MF). https://notreload.xyz/fda-clears-lacutamab-confirmatory-phase-3-ctcl-trial-protocol/
0 · Reply
BearTamerTrading
BearTamerTrading Nov. 10 at 4:44 PM
🚀 Premarket Power Plays — Bear Tamer Trading Community Wins 🔥 Part 2/3 The following plays were called LIVE during premarket before the crowd: 🔥 $GLTO — 323% move off cell-therapy data re-rating/press release 🔥 $OGN — Broad Women’s Health spin-out momentum & product update 🔥 $IPHA — Pipeline progress announcement in dermatology/auto-immune space 🔥 $RUM — Video-platform commentary surge & speculative breakout play. Members were already in position before the volume spike 💪 If you missed it, watch the replay for proof — testimonials are in the comments ⬇️ 🎥 Replay Link: https://www.youtube.com/live/vlYDstPoN2w?si=sy_JgV1cEZVx78Vf
4 · Reply
UltimateWackDumbtrader27
UltimateWackDumbtrader27 Nov. 10 at 4:43 PM
$IPHA hereeeee halty up, halty up, halty up…..here boy….
0 · Reply
bowlerhatsftw
bowlerhatsftw Nov. 10 at 4:18 PM
$IPHA vwap surge
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 10 at 4:03 PM
$IPHA has popped 4% higher to 19% (~9Mv) in the last few minutes, follow for more volatility.
0 · Reply
jdlman
jdlman Nov. 10 at 2:57 PM
$IPHA nice
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 10 at 1:39 PM
$IPHA Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
0 · Reply
Ididize
Ididize Nov. 10 at 1:29 PM
$GLTO $IPHA https://finance.yahoo.com/news/innate-pharma-receives-us-fda-094558492.html
0 · Reply
Ididize
Ididize Nov. 10 at 1:24 PM
$IPHA $GLTO 🚀
0 · Reply
marycha
marycha Nov. 10 at 12:19 PM
$IPHA Looks like it is about to go
0 · Reply
hockeyfan530
hockeyfan530 Nov. 10 at 12:03 PM
$IPHA in
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 10 at 11:56 AM
IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers $IPHA $CNCR https://stocktwits.com/news/equity/markets/ipha-stock-soars-pre-marker-after-fda-clears-late-stage-trial-for-lacutamab-in-rare-skin-cancers/cLPc04NRE2R
0 · Reply
MS_Tammy
MS_Tammy Nov. 10 at 11:50 AM
Morning everyone, who is here.. day trading day.... remember don't be greedy , be quick ... any win is a win.. Keep your eyes on $IPHA .. zero borrows has FDA news.. and EZY found ATM warrants @ 2.05. Warrants @ 2.38 (Lots). lets have a fabulous week together..
7 · Reply